Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791274 | 1.00 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL7126306 | 0.96 | ITGAV (0.48) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL4790853 | 0.94 | ITGAV (0.46) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL4789561 | 0.86 | ITGAV (0.57) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL4791224 | 0.86 | ITGAV (0.57) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL4718204 | 0.84 | ITGAV (0.49) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL14221976 | 0.83 | ITGB3 (0.53) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL4790825 | 0.81 | ITGB3 (0.54) | ITGAVITGB3ITGB5ITGA2BITGB1 | |
| SCHEMBL4791427 | 0.81 | ITGAV (0.54) | ITGAVITGB6ITGB3ITGB5ITGA2B | |
| SCHEMBL14222263 | 0.80 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | claimed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | claimed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |